Status:
COMPLETED
Efficacy of a Multimodal Brain Health Intervention for Older African Americans
Lead Sponsor:
Oregon Health and Science University
Collaborating Sponsors:
National Center for Advancing Translational Sciences (NCATS)
Oregon Clinical and Translational Research Institute
Conditions:
Cognitive Impairment, Mild
Cognitive Decline
Eligibility:
All Genders
65-110 years
Phase:
NA
Brief Summary
This study tests the feasibility, acceptability, and efficacy of a multimodal intervention (walking, social engagement, and reminiscence), including the use of wearable digital biomarkers, for cogniti...
Detailed Description
Cognitively healthy and mildly cognitively impaired participants engage in up to 8 weeks of baseline data collection and 4-16 weeks of triadic neighborhood walking using a group tablet device to acces...
Eligibility Criteria
Inclusion
- Inclusion Criteria for walkers:
- Self-identified African American,
- Age \> 65 years old
- Reside or resided for \>10 years in Portland's historically Black neighborhoods (to be familiar with Memory Markers about this area),
- Able to ambulate independently.
- Meeting Cognition Criteria
- Participants with MCI (Mild Cognitive Impairment) will meet criteria consistent with the criteria outlined by the NIA-Alzheimer's Association workgroup
- Participants without cognitive impairment will have a Montreal Cognitive Assessment (MoCA) score \> 24 (and not meet MCI criteria). Participants' cognitive function should allow them to get to and from walk locations independently or with minimal assistance.
- Cognitive function allows independent (or minimally assisted) travel to and from walk locations
- In-home reliable broadband internet (for weekly online surveys).
- Ability to read, speak, and understand English
- Exclusion Criteria:
- Self-reported or clinically diagnosed dementia
- Significant disease of the central nervous system
- Severely depressed (CES-D score \> 16), significantly symptomatic psychiatric disorder
- Advanced cardiovascular disease that would make walking difficult, including history of congestive heart failure
- Unstable insulin-dependent diabetes mellitus, received diagnosis Type 1 Diabetes, started insulin within past 3 months, hospitalized for hypoglycemia within past 6 months.
Exclusion
Key Trial Info
Start Date :
February 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2023
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT04863378
Start Date
February 1 2022
End Date
October 1 2023
Last Update
January 6 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oregon Health & Science University
Portland, Oregon, United States, 97239